REFERENCES

1. Mamas MA, Brown SA, Sun LY. Coronary artery disease in patients with cancer: It's always the small pieces that make the bigger picture. Mayo Clin Proc. 2020; 95(9): 1819–1821, doi: 10.1016/j.mayocp.2020.07.006, indexed in Pubmed: 32861320.
2. Wang Z, Fan Z, Yang L, et al. Higher risk of cardiovascular mortality than cancer mortality among long-term cancer survivors. Front Cardiovasc Med. 2023; 10: 1014400, doi: 10.3389/fcvm.2023.1014400, indexed in Pubmed: 36760569.
3. Cancer society. Cancer Treatment & Survivorship Facts & Figures 2019--2021; 2019.
4. Statistics and graphs. Office of Cancer survivorship. National Cancer institute: Division of cancer control & population sciences. Nov 2022. https://cancercontrol.cancer.gov/ocs/statistics#stats (accessed: January 11, 2024).
5. Koene RJ, Prizment AE, Blaes A, et al. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016; 133(11): 1104–1114, doi: 10.1161/CIRCULATIONAHA.115.020406, indexed in Pubmed: 26976915.
6. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010; 15(6): 556–565, doi: 10.1634/theoncologist.2009-0285, indexed in Pubmed: 20507889.
7. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010; 33(7): 1674–1685, doi: 10.2337/dc10-0666, indexed in Pubmed: 20587728.
8. Costa IB, Andrade FT, Carter D, et al. Challenges and management of acute coronary syndrome in cancer patients. Front Cardiovasc Med. 2021; 8: 590016, doi: 10.3389/fcvm.2021.590016, indexed in Pubmed: 34179121.
9. Grossman E, Messerli FH, Boyko V, et al. Is there an association between hypertension and cancer mortality? Am J Med. 2002; 112(6): 479–486, doi: 10.1016/s0002-9343(02)01049-5, indexed in Pubmed: 11959059.
10. Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020; 22(11): 1945–1960, doi: 10.1002/ejhf.1920, indexed in Pubmed: 32463967.
11. Caine GJ, Stonelake PS, Lip GYH, et al. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002; 4(6): 465–473, doi: 10.1038/sj.neo.7900263, indexed in Pubmed: 12407439.
12. Potts JE, Iliescu CA, Lopez Mattei JC, et al. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur Heart J. 2019; 40(22): 1790–1800, doi: 10.1093/eurheartj/ehy769, indexed in Pubmed: 30500952.
13. Doolub G, Mamas MA. Percutaneous coronary angioplasty in patients with cancer: Clinical challenges and management strategies. J Pers Med. 2022; 12(9): 1372, doi: 10.3390/jpm12091372, indexed in Pubmed: 36143156.
14. Yadav M, Généreux P, Giustino G, et al. Effect of baseline thrombocytopenia on ischemic outcomes in patients with acute coronary syndromes who undergo percutaneous coronary intervention. Can J Cardiol. 2016; 32(2): 226–233, doi: 10.1016/j.cjca.2015.05.020, indexed in Pubmed: 26341303.
15. Johnstone C, Rich SE. Bleeding in cancer patients and its treatment: A review. Ann Palliat Med. 2018; 7(2): 265–273, doi: 10.21037/apm.2017.11.01, indexed in Pubmed: 29307210.
16. Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019; 40(31): 2632–2653, doi: 10.1093/eurheartj/ehz372, indexed in Pubmed: 31116395.
17. Raposeiras-Roubín S, Abu-Assi E, Muñoz-Pousa I, et al. Usefulness of bleeding after acute coronary syndromes for unmasking silent cancer. Am J Cardiol. 2020; 125(12): 1801–1808, doi: 10.1016/j.amjcard.2020.03.023, indexed in Pubmed: 32307091.
18. Kirresh A, White L, Mitchell A, et al. Radiation-induced coronary artery disease: a difficult clinical conundrum. Clin Med (Lond). 2022; 22(3): 251–256, doi: 10.7861/clinmed.2021-0600, indexed in Pubmed: 35584837.
19. Borges N, Kapadia S. Radiation-induced CAD: incidence, diagnosis, and management outcomes. American College of Cardiology. 2018. https://www.acc.org/Latest-in-Cardiology/Articles/2018/05/24/01/44/Radiation-Induced-CAD (accessed: January 11, 2024).
20. Cuomo JR, Javaheri SP, Sharma GK, et al. How to prevent and manage radiation-induced coronary artery disease. Heart. 2018; 104(20): 1647–1653, doi: 10.1136/heartjnl-2017-312123, indexed in Pubmed: 29764968.
21. Wu W, Masri A, Popovic ZB, et al. Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study. Circulation. 2013; 127(14): 1476–1485, doi: 10.1161/CIRCULATIONAHA.113.001435, indexed in Pubmed: 23569119.
22. Reed GW, Rossi JE, Masri A, et al. Long-Term mortality in patients with radiation-associated coronary artery disease treated with percutaneous coronary intervention. Circ Cardiovasc Interv. 2016; 9(6): e003483, doi: 10.1161/CIRCINTERVENTIONS.115.003483, indexed in Pubmed: 27313281.
23. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022; 43(41): 4229–4361, doi: 10.1093/eurheartj/ehac244, indexed in Pubmed: 36017568.
24. Mohamed MO, Van Spall HGC, Kontopantelis E, et al. Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis. Eur Heart J Acute Cardiovasc Care. 2021; 10(8): 829–839, doi: 10.1093/ehjacc/zuaa032, indexed in Pubmed: 33587752.
25. Balanescu DV, Donisan T, Deswal A, et al. Acute myocardial infarction in a high-risk cancer population: Outcomes following conservative versus invasive management. Int J Cardiol. 2020; 313: 1–8, doi: 10.1016/j.ijcard.2020.04.050, indexed in Pubmed: 32320781.
26. Bharadwaj A, Potts J, Mohamed MO, et al. Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA. Eur Heart J. 2020; 41(23): 2183–2193, doi: 10.1093/eurheartj/ehz851, indexed in Pubmed: 31800032.
27. Guddati AK, Joy PS, Kumar G. Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a 10-year period. J Cancer Res Clin Oncol. 2016; 142(2): 471–479, doi: 10.1007/s00432-015-2056-5, indexed in Pubmed: 26498773.
28. Beltrame JF. Assessing patients with myocardial infarction and nonobstructed coronary arteries (MINOCA). J Intern Med. 2013; 273(2): 182–185, doi: 10.1111/j.1365-2796.2012.02591.x, indexed in Pubmed: 22998397.
29. Agewall S, Beltrame JF, Reynolds HR, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017; 38(3): 143–153, doi: 10.1093/eurheartj/ehw149, indexed in Pubmed: 28158518.
30. Stepien K, Nowak K, Szlosarczyk B, et al. Clinical characteristics and long-term outcomes of MINOCA accompanied by active cancer: A retrospective insight into a Cardio-Oncology Center Registry. Front Cardiovasc Med. 2022; 9: 785246, doi: 10.3389/fcvm.2022.785246, indexed in Pubmed: 35669480.
31. Zaghlol R, Dey A, Barac A. Takotsubo and cancer: Takotsubo cardiomyopathy in the era of emerging cancer therapies. Eur Heart J. 2020; 41(48): 4547–4549, doi: 10.1093/eurheartj/ehaa175.
32. Sattler K, El-Battrawy I, Gietzen T, et al. Prevalence of cancer in Takotsubo cardiomyopathy: Short and long-term outcome. Int J Cardiol. 2017; 238(7): 159–165, doi: 10.1016/j.ijcard.2017.02.093, indexed in Pubmed: 28318661.
33. Zaghlol R, Kashyap K, Al-Shbool G, et al. Usefulness of malignancy as a predictor of worsein-hospital outcomes in patients with takotsubo cardiomyopathy. Am J Cardiol. 2019; 123(6): 995–1001, doi: 10.1016/j.amjcard.2018.11.054, indexed in Pubmed: 30595393.
34. El-Battrawy I, Santoro F, Stiermaier T, et al. Prevalence and long-term prognostic impact of malignancy in patients with Takotsubo syndrome. Eur J Heart Fail. 2018; 20(4): 816–818, doi: 10.1002/ejhf.868, indexed in Pubmed: 28849607.

35. Agewall S, Beltrame JF, Reynolds HR, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017; 38(3): 143–153, doi: 10.1093/eurheartj/ehw149, indexed in Pubmed: 28158518.
36. Dastidar AG, Baritussio A, De Garate E, et al. Prognostic role of CMR and conventional risk factors in myocardial infarction with nonobstructed coronary arteries. JACC Cardiovasc Imaging. 2019; 12(10): 1973–1982, doi: 10.1016/j.jcmg.2018.12.023, indexed in Pubmed: 30772224.
37. Ferrante G, Rao SV, Jüni P, et al. Radial versus femoral access for coronary interventions across the entire spectrum of patients with coronary artery disease: a meta-analysis of randomized trials. JACC Cardiovasc Interv. 2016; 9(14): 1419–1434, doi: 10.1016/j.jcin.2016.04.014, indexed in Pubmed: 27372195.
38. Gargiulo G, Giacoppo D, Jolly SS, et al. Effects on mortality and major bleeding of radial versus femoral artery access for coronary angiography or percutaneous coronary intervention: meta-analysis of individual patient data from 7 multicenter randomized clinical trials. Circulation. 2022; 146(18): 1329–1343, doi: 10.1161/CIRCULATIONAHA.122.061527, indexed in Pubmed: 36036610.
39. Valgimigli M, Saia F, Guastaroba P, et al. Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell'Emilia-Romagna) multicenter registry. JACC Cardiovasc Interv. 2012; 5(1): 23–35, doi: 10.1016/j.jcin.2011.08.018, indexed in Pubmed: 22230147.
40. Seto AH, Roberts JS, Abu-Fadel MS, et al. Real-time ultrasound guidance facilitates transradial access: RAUST (Radial Artery access with Ultrasound Trial). JACC Cardiovasc Interv. 2015; 8(2): 283–291, doi: 10.1016/j.jcin.2014.05.036, indexed in Pubmed: 25596790.
41. Munoz-Gonzalez, E. et al. PCI in patients with cancer. Cardiac Interventions Today. https://citoday.com/articles/2019-jan-feb/pci-in-patients-with-cancer (accessed: February 25, 2024).
42. Mehta SR, Wood DA, Storey RF, et al. Complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med. 2019; 381(15): 1411–1421, doi: 10.1056/nejmoa1907775, indexed in Pubmed: 31475795.
43. Kim JW, Dayah TJ, Javaid A, et al. Reclassification of treatment strategy with fractional flow reserve in cancer patients with coronary artery disease. Medicina (Kaunas). 2022; 58(7): 884, doi: 10.3390/medicina58070884, indexed in Pubmed: 35888603.
44. Donisan T, Dayah T, Balanescu D, et al. Clinical outcomes after fractional flow reserve-guided treatment of oncology patients. J Clin Oncol. 2018; 36(Suppl 15): e22106, doi: 10.1200/jco.2018.36.15_suppl.e22106.
45. Madder RD, Seth M, Sukul D, et al. Rates of intracoronary imaging optimization in contemporary percutaneous coronary intervention: a report from the BMC2 registry. Circ Cardiovasc Interv. 2022; 15(10): e012182, doi: 10.1161/CIRCINTERVENTIONS.122.012182, indexed in Pubmed: 36256694.
46. Munoz-Gonzalez E, Poulin MF, Goel M, et al. PCI in patients with cancer: Approaches for successfully treating this challenging patient population when invasive coronary procedures are needed. Cardiac Interventions Today. 2019.
47. de la Torre Hernandez JM, Hernandez FH, Alfonso F, et al. Prospective application of pre-defined intravascular ultrasound criteria for assessment of intermediate left main coronary artery lesions. J Am Coll Cardiol. 2011; 58(4): 351–358, doi: 10.1016/j.jacc.2011.02.064, indexed in Pubmed: 21757111.
48. Richards G, Johnson T. A vision of percutaneous coronary revascularisation in 2021: How to take advantage of intra-coronary imaging to perform more effective PCI. JRSM Cardiovasc Dis. 2021; 10: 20480040211049978, doi: 10.1177/20480040211049978, indexed in Pubmed: 35186282.
49. Räber L, Mintz GS, Koskinas KC, et al. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Eur Heart J. 2018; 39(35): 3281–3300, doi: 10.1093/eurheartj/ehy285, indexed in Pubmed: 29790954.
50. Johnson TW, Räber L, Di Mario C, et al. Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Eur Heart J. 2019; 40(31): 2566–2584, doi: 10.1093/eurheartj/ehz332, indexed in Pubmed: 31112213.
51. Lotfi A, Jeremias A, Fearon WF, et al. Expert consensus statement on the use of fractional flow reserve, intravascular ultrasound, and optical coherence tomography: a consensus statement of the Society of Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2014; 83(4): 509–518, doi: 10.1002/ccd.25222, indexed in Pubmed: 24227282.
52. Iliescu CA, Cilingiroglu M, Giza DE, et al. „Bringing on the light" in a complex clinical scenario: Optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry). Am Heart J. 2017; 194: 83–91, doi: 10.1016/j.ahj.2017.08.015, indexed in Pubmed: 29223438.
53. Valgimigli M, Patialiakas A, Thury A, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015; 65(8): 805–815, doi: 10.1016/j.jacc.2014.11.053.
54. Ariotti S, Adamo M, Costa F, et al. Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention?: a pre-specified analysis from the ZEUS trial. JACC Cardiovasc Interv. 2016; 9(5): 426–436, doi: 10.1016/j.jcin.2015.11.015, indexed in Pubmed: 26965932.
55. Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015; 373(21): 2038–2047, doi: 10.1056/NEJMoa1503943, indexed in Pubmed: 26466021.
56. Windecker S, Latib A, Kedhi E, et al. Polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J Med. 2020; 382(13): 1208–1218, doi: 10.1056/nejmoa1910021, indexed in Pubmed: 32050061.
57. Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019; 381(21): 2032–2042, doi: 10.1056/NEJMoa1908419, indexed in Pubmed: 31556978.
58. Jeger RV, Eccleshall S, Wan Ahmad WA, et al. Drug-coated balloons for coronary artery disease: Third report of the international DBC consensus group. JACC Cardiovasc Interv. 2020; 13(12): 1391–1402, doi: 10.1016/j.jcin.2020.02.043, indexed in Pubmed: 32473887.
59. Latib A, Colombo A, Castriota F, et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. J Am Coll Cardiol. 2012; 60(24): 2473–2480, doi: 10.1016/j.jacc.2012.09.020, indexed in Pubmed: 23158530.
60. Mathey DG, Wendig I, Boxberger M, et al. Treatment of bifurcation lesions with a drug-eluting balloon: the PEPCAD V (Paclitaxel Eluting PTCA Balloon in Coronary Artery Disease) trial. EuroIntervention. 2011; 7 Suppl K: K61–K65, doi: 10.4244/EIJV7SKA11, indexed in Pubmed: 22027730.
61. Scheller B, Ohlow MA, Ewen S, et al. Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial. EuroIntervention. 2020; 15(17): 1527–1533, doi: 10.4244/EIJ-D-19-00723, indexed in Pubmed: 31659986.
62. Valgimigli M, Smits PC, Frigoli E, et al. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis. Eur Heart J. 2022; 43(33): 3100–3114, doi: 10.1093/eurheartj/ehac284, indexed in Pubmed: 35580836.
63. Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019; 321(24): 2414–2427, doi: 10.1001/jama.2019.8145, indexed in Pubmed: 31237644.
64. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2023; 44(38): 3720–3826, doi: 10.1093/eurheartj/ehad191, indexed in Pubmed: 37622654.
65. Leszek P, Klotzka A, Bartuś S, et al. A practical approach to the 2022 ESC cardio-oncology guidelines: Comments by a team of experts - cardiologists and oncologists. Kardiol Pol. 2023; 81(10): 1047–1063, doi: 10.33963/v.kp.96840, indexed in Pubmed: 37660389.